Oxygen, oxidative stress, hypoxia, and heart failure

Journal of Clinical Investigation

Volumn 115, Issue 3, 2005, Pages 500-508

  Giordano, Frank J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; HYDRALAZINE; ION CHANNEL; ISOSORBIDE DINITRATE; LIPID; NITRIC OXIDE; OXYGEN; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE;

ACUTE HEART INFARCTION; APOPTOSIS; CALCIUM TRANSPORT; CLINICAL TRIAL; DRUG EFFICACY; DRUG INHIBITION; EXCITATION CONTRACTION COUPLING; GENE EXPRESSION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART VENTRICLE HYPERTROPHY; HUMAN; LIPID STORAGE; NONHUMAN; OXIDATIVE STRESS; OXYGEN SUPPLY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

ANIMALS; ANOXIA; CALCIUM; CARDIAC OUTPUT, LOW; ENERGY METABOLISM; GENE EXPRESSION REGULATION; HUMANS; HYPERTROPHY; ION CHANNELS; LIPIDS; MITOCHONDRIA; MYOCARDIAL ISCHEMIA; MYOCARDIUM; OXIDATIVE STRESS; OXYGEN; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 14644442283     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI200524408     Document Type: Review

References (125)

1. West, J.B. 1991. Cardiac energetics and myocardial oxygen consumption. Physiologic basis of medical practice. Williams and Wilkins. Baltimore, Maryland, USA. 250-260.
2. Braunwald, E. 2001. Coronary blood flow and myocardial ischemia. Heart disease: a textbook of cardiovascular medicine. W.B. Saunders Company. Philadelphia, Pennsylvania, USA. 1161-1183.
3. Huang, Y., et al. 2004. Cardiac myocyte-specific HIF-1alpha deletion alters vascularization, energy availability, calcium flux, and contractility in the normoxic heart. FASEB J. 18:1138-1140.
4. Davies, KJ. 1995. Oxidative stress: the paradox of aerobic life. Biochem. Soc. Symp. 61:1-31.
5. Jafri, M.S., Dudycha, S.J., and O'Rourke, B. 2001. Cardiac energy metabolism: models of cellular respiration. Annu. Rev. Biomed. Eng. 3:57-81.
6. Ide, T., et al. 1999. Mitochondrial electron transport complex I is a potential source of oxygen free radicals in the failing myocardium. Circ. Res. 85:357-363.
7. Miwa, S., and Brand, M.D. 2003. Mitochondrial matrix reactive oxygen species production is very sensitive to mild uncoupling. Biochem. Soc. Trans. 31:1300-1301.
8. Genova, M.L., et al. 2003. Mitochondrial production of oxygen radical species and the role of Coenzyme Q as an antioxidant. Exp. Biol. Med. (Maywood). 228:506-513.
9. Toufektsian, M.C., Boucher, F.R., Tanguy, S., Morel, S., and de Leiris, J.G. 2001. Cardiac toxicity of singlet oxygen: implication in reperfusion injury. Antioxid. Redox. Signal. 3:63-69.
10. Seshiah, P.N., et al. 2002. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ. Res. 91:406-413.
11. Xia, Y., Tsai, A.L., Berka, V., and Zweier, J.L. 1998. Superoxide generation from endothelial nitricoxide synthase. A Ca2+/calmodulin-dependent and retrahydrobiopterin regularoiy process. J. Biol. Chem. 273:25804-25808.
12. Xia, Y., Roman, L.J., Masters, B.S., and Zweier, J.L. 1998. Inducible nitric-oxide synthase generates Superoxide from the reductase domain. J. Biol. Chem. 273:22635-22639.
13. Griendling, K.K., Sorescu, D., and Ushio-Fukai, M. 2000. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res. 86:494-501.
14. Sawyer, D.B., et al. 2002. Role of oxidative stress in myocardial hypertrophy and failure. J. Mol. Cell. Cantiol. 34:379-388.
15. Thannickal, V.J., and Fanburg, B.L. 2000. Reactive oxygen species in cell signaling. Am. J. Physiol. Lung Cell Mol. Physiol. 279:L1005-L1028.
16. Bendall, J.K., Cave, A.C., Heymes, C, Gall, N., and Shah, A.M. 2002. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation. 105:293-296.
17. Wu, M.L., Chan, C.C., and Su, M.J. 2000. Possible mechanism(s) of arachidonic acid-induced intracellular acidosis in rat cardiac myocyres. Circ. Res. 86:E55-E62.
18. Sauer, H., et al. 2004. Involvement of reactive oxygen species in cardiotrophin-1-induced proliferation of cardiomyocytes differentiated from murine embryonic srem cells. Exp. Cell Res. 294:313-324.
19. Heymes, C., et al. 2003. Increased myocardial NADPH oxidase activity in human heart failure. J. Am. Coll Cardial. 41:2164-2171.
20. Sabri, A., Hughie, H.H., and Lucchesi, P.A. 2003. Regulation of hypertrophic and apoptotic signaling pathways by reactive oxygen species in cardiac myocytes. Antioxid. Redox Signal. 5:731-740.
21. Nordberg, J., and Arner, E.S. 2001. Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radic. Biol. Med. 31:1287-1312.
22. Kirkman, H.N., and Gaetani, G.F. 1984. Catalase: a tetrameric enzyme with four tightly bound molecules of NADPH. Proc. Natl. Acad. Sci. U. S. A. 81:4343-4347.
23. Kirkman, H.N., Rolfo, M., Ferraris, A.M., and Gaetani, G.F. 1999. Mechanisms of protection of catalase by NADPH. Kinetics and stoichiometry. J. Biol. Chem. 274:13908-13914.
24. Ursini, F., et al. 1995. Diversity of glutathione peroxidases. Methods Enzymol 252:38-53.
25. de Haan, J.B., et al. 2004. Fibroblasts derived from Gpx1 knockout mice display senescent-like features and are susceptible to H2O2-mediated cell death. Free. Radic. Biol. Med. 36:53-64.
26. Conrad, M., et al. 2004. Essential role for mitochondrial thioredoxin reductase in hematopoiesis, heart development, and heart function. Mol. Cell. Biol. 24:9414-9423.
27. Hensley, K., Robinson, K.A., Gabbita, S.P., Salsman, S., and Floyd, R.A. 2000. Reactive oxygen species, cell signaling, and cell injury. Free Radic. Biol. Med. 28:1456-1462.
28. Nishida, M., et al. 2000. G alpha(i) and G alpha(o) are target proteins of reactive oxygen species. Nature. 408:492-495.
29. Griendling, K.K., and FitzGerald, G.A. 2003, Oxidative stress and cardiovascular injury: part I: basic mechanisms and in vivo monitoring of ROS. Circulation. 108:1912-1916.
30. Machida, Y., et al. 2003. Overexpression of tumor necrosis factor-alpha increases production of hydroxyl radical in murine myocardium. Am. J. Physiol. Heart Circ. Physiol. 284:H449-H455.
31. Hirotani, S., et al. 2002. Involvement of nuclear factor-kappaB and apoptosis signal-regulating kinase 1 in G-protein-coupled receptor agonist-induced cardiomyocyte hypertrophy. Circulation. 105:509-515.
32. Hsu, T.C, Young, M.R., Cmarik, J., and Colburn, N.H. 2000. Activator protein 1 (AP-1)- and nuclear factor kappaB (NF-kappaB)-dependent transcriptional events in carcinogenesis. Free Radic. Biol. Med. 28:1338-1348.
33. Turpaev, K.T. 2002. Reactive oxygen species and regulation of gene expression. Biochemistry Mosc. 67:281-292.
34. Wu, H.M., Chi, K.H., and Lin, W.W. 2002. Proteasome inhibitors stimulate activator protein-1 pathway via reactive oxygen species production. FEBS Lett. 526:101-105.
35. Hemnani, T., and Parihar, M.S. 1998. Reactive oxygen species and oxidative DNA damage. Indian J. Physiol. Pharmacol. 42:440-452.
36. Suematsu, N., et al. 2003. Oxidative stress mediates tumor necrosis factor-alpha-induced mitochondrial DNA damage and dysfunction in cardiac myocytes. Circulation. 107:1418-1423.
37. Rathore, N., John, S., Kale, M., and Bhatnagar, D. 1998. Lipid peroxidation and antioxidant enzymes in isoproterenol induced oxidative stress in rat tissues. Pharmacol. Res. 38:297-303.
38. Thollon, C., Iliou, J.P., Cambarrat, C., Robin, F., and Vilaine, J.P. 1995. Nature of the cardiomyocyte injury induced by lipid hydroperoxides. Cardiovasc. Res. 30:648-655.
39. Rahman, I.2003. Oxidative stress, chromatin remodeling and gene transcription in inflammation and chronic lung diseases. J. Biochem. Mol. Biol. 36:95-109.
40. Konat, G.W. 2003. H2O2-induced higher order chromatin degradation: a novel mechanism of oxidative genotoxicity. J. Biosci. 28:57-60.
41. Lockwood, T.D. 2000. Redox control of protein degradation. Antioxid. Redox Signal. 2:851-878.
42. Stadtman, E.R., and Levine, R.L. 2003. Free radical-mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids. 25:207-218.
43. Sinclair, D.A. 2002. Paradigms and pitfalls of yeast longevity research. Mech. Ageing Dev. 123:857-867.
44. Lakatta, E.G. 2003. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part III: cellular and molecular clues to heart and arterial aging. Circulation. 107:490-497.
45. Wallace, D.C. 2001. Mouse models for mitochondrial disease, Am. J. Med. Genet. 106:71-93.
46. Scortegagna, M., et al. 2003. Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice. Nat. Genet. 35:331-340.
47. Cesselli, D., et al. 2001. Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ. Res. 89:279-286.
48. Ho, Y.S., Magnenat, J.L., Gargano, M., and Cao, J. 1998. The nature of antioxidant defense mechanisms: a lesson from transgenic studies. Environ. Health Perspect. 106(Suppl. 5):1219-1228.
49. Yen, H.C., Oberley, T.D., Vichitbandha, S., Ho, Y.S., and St. Clair, D.K. 1996. The protective role of manganese Superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J. Clin. Invest. 98:1253-1260.
50. Chen, E.P., Bittner, H.B., Davis, R.D., Folz, R.J., and Van Trigt, P. 1996. Extracellular Superoxide dismutase transgene overexpression preserves postischemic myocardial function in isolated murine hearts. Circulation. 94:II412-II417.
51. Pennathur, S., Wagner, J.D., Leeuwenburgh, C., Litwak, K.N., and Heinecke, J.W. 2001. A hydroxyl radical-like species oxidizes cynomolgus monkey artery wall proteins in early diabetic vascular disease. J. Clin. Invest. 107:853-860.
52. Khatti, J.J., et al. 2004. Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation. 109:520-525.
53. Witztum, J.L, and Steinberg, D. 1991. Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88:1785-1792.
54. Rajagopaian, S., Meng, X.P., Ramasamy, S., Harrison, D.G., and Galis, Z.S. 1996. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J. Clin. Invest. 98:2572-2579.
55. Asimakis, G.K., Lick, S., and Patterson, C. 2002. Postischemic recovery of contractile function is impaired in SOD2(+/-) but not SOD1(+/-) mouse hearts. Circulation. 105:981-986.
56. Yoshida, T., Maulik, N., Engelman, R.M., Ho, Y.S., and Das, D.K. 2000. Targeted disruption of the mouse Sod I gene makes the hearts vulnerable to ischemic reperfusion injury. Circ. Res. 86:264-269.
57. Bolli, R. 1998. Causative role of oxyradicals in myocardial stunning: a proven hypothesis. A brief review of the evidence demonstrating a major role of reactive oxygen species in several forms of postischemic dysfunction. Basic Res. Cardiol. 93:156-162.
58. Perez, N.G., Gao, W.D., and Marban, E. 1998. Novel myofilament Ca2+-sensitizing property of xanthine oxidase inhibitors. Circ. Res. 83:423-430.
59. Charlat, M.I., et al. 1987. Evidence for a pathogenetic role of xanthine oxidase in the "stunned" myocardium. Am. J. Physiol. 252:H566-H577.
60. Pfeffer, M.A., and Braunwald, E. 1990. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circculation. 81:1161-1172.
61. Mann, D.L., and Spinale, F.G. 1998. Activation of matrix metalloproteinases in the failing human heart: breaking the tie that binds. Circulation. 98:1699-1702.
62. von Harsdorf, R., Li, P.F., and Dietz, R. 1999. Signaling pathways in reactive oxygen species-induced cardiomyocyte apoptosis. Circulation. 99:2934-2941.
63. Engberding, N., et al. 2004. Allopurinol attenuates left ventricular remodeling and dysfunction after experimental myocardial infarction: a new action for an old drug? Circulation. 110:2175-2179.
64. Kwon, S.H., Pimentel, D.R., Remondino, A., Sawyer, D.B., and Colucci, W.S. 2003. H(2)O(2) regulates cardiac myocyte phenotype via concentrationdependent activation of distinct kinase pathways. J. Mol. Cell. Cardiol. 35:615-621.
65. Li, J.M., Gall, N.P., Grieve, D.J., Chen, M., and Shah, A.M. 2002. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension. 40:477-484.
66. Date, M.O., et al. 2002. The antioxidant N-2-mercaptopropionyl glycine attenuates left ventricular hypertrophy in in vivo murine pressure-overload model J. Am. Coll. Cardiol. 39:907-912.
67. Higuchi, Y., et al. 2002. Involvement of reactive oxygen species-mediated NF-kappa B activation in TNF-alpha-induced cardiomyocyte hypertrophy. J. Mol. Cell. Cardiol. 34:233-240.
68. Pimentel, D.R., et al. 2001. Reactive oxygen species mediate amplitude-dependent hypertrophic and apoptotic responses to mechanical stretch in cardiac myocytes. Circ. Res. 89:453-460.
69. Ghosh, M.C., Wang, X., Li, S., and Klee, C. 2003. Regulation of calcineurin by oxidative stress. Methods Enzymol. 366:289-304.
70. Gopalakrishna, R., Gundimeda, U., and Chen, Z.H. 1997. Cancer-preventive selenocompounds induce a specific redox modification of cysteine-rich regions in Ca(2+)-dependent isoenzymes of protein kinase C. Arch. Biochem. Biophys. 348:25-36.
71. Nakamura, K., et al. 1998. Inhibitory effects of antioxidants on neonatal rat cardiac myocyte hypertrophy induced by tumor necrosis factor-alpha and angiotensin II. Circulation. 98:794-799.
72. Delbosc, S., Cristol, J.P., Descomps, B., Mimran, A., and Jover, B. 2002. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension. 40:142-147.
73. Sugden, P.H., and Clerk, A. 1998. "Stress-responsive" mitogen-activated protein kinases (c-Jun N-terminal kinases and p38 mitogen-activated protein kinases) in the myocardium. Circ. Res. 83:345-352.
74. Takemoto, M., et al. 2001. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J. Clin. Invest. 108:1429-1437. doi:10.1172/JCI200113350.
75. Izumiya, Y., et al. 2003. Apoptosis signal-regulating kinase 1 plays a pivotal role in angiotensin II-induced cardiac hypertrophy and remodeling. Circ. Res. 93:874-883.
76. Gotoh, Y., and Cooper, J.A. 1998. Reactive oxygen, species- and dimerization-induced activation of apoptosis signal-regulating kinase 1 in tumor necrosis factor-alpha signal transduction. J. Biol. Chem. 273:17477-17482.
77. Yamaguchi, O., et al. 2003. Targeted deletion of apoptosis signal-regulating kinase 1 attenuates left ventricular remodeling. Proc. Natl.. Acad. Sci. U. S. A. 100:15883-15888.
78. Rayment, N.B., et al. 1999. Myocyte loss in chronic heart failure. J. Pathol. 188:213-219.
79. Adeghate, E. 2004. Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: a short review. Mol. Cell. Biochem. 261:187-191.
80. Remondino, A., et al. 2003. Beta-adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH2-terminal kinase-dependent activation of the mitochondrial pathway. Circ. Res. 92:136-138.
81. Kourie, J.I. 1998. Interaction of reactive oxygen species with ion transport mechanisms. Am. J. Physiol. 275:C1-C24.
82. Guerra, L., Cerbai, E., Gessi, S., Borea, P.A., and Mugelli, A. 1996. The effect of oxygen free radicals on calcium current and dihydropyridine binding sites in guinea-pig ventricular myocytes. Br. J. Pharmacol. 118:1278-1284.
83. Kaplan, P., Babusikova, E., Lehotsky, J., and Dobrota, D. 2003. Free radical-induced protein modification and inhibition of Ca2+-ATPase of cardiac sarcoplasmic reticulum. Mol. Cell. Biochem. 248:41-47.
84. Nakaya, H., Takeda, Y., Tohse, N., and Kanno, M. 1992. Mechanism of the membrane depolarization induced by oxidative stress in guinea-pig ventricular cells. J. Mol. Cell. Cardiol. 24:523-534.
85. Goldhaber, J.I. 1996. Free radicals enhance Na+/Ca2+ exchange in ventricular myocytes. Am. J. Physiol. 271:H823-H833.
86. He, X., et al. 2003. ASK1 associates with troponin T and induces troponin T phosphorylation and contractile dysfunction in cardiomyocytes. Am. J. Pathol. 163:243-251.
87. Unger, R.H. 2002. Lipotoxic diseases. Annu. Rev. Med. 53:319-336.
88. Sharma, S., et al. 2004. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J. 18:1692-1700.
89. Finck, B.N., et al. 2003. A critical role for PPARalpha-mediated lipotoxicity in the pathogenesis of diabetic cardiomyopathy: modulation by dietary fat content. Proc. Natl. Acad. Sci. U. S. A. 100:1226-1231.
90. Balligand, J.L., Kelly, R.A., Marsden, P.A., Smith, T.W., and Michel, T. 1993. Control of cardiac muscle cell function by an endogenous nitric oxide signaling system. Proc. Natl. Acad. Sci. U. S. A. 90:347-351.
91. Bonaventura, J., and Gow, A. 2004. NO and superoxide: opposite ends of the seesaw in cardiac contractility. Proc. Natl. Acad. Sci. U. S. A. 101:16403-16404.
92. Khan, S.A., et al. 2004. Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling. Proc. Natl. Acad. Sci. U. S. A. 101:15944-15948.
93. Gaston, B.M., Carver, J., Doctor, A., and Palmer, L.A. 2003. S-nitrosylation signaling in cell biology. Mol. Interv. 3:253-263.
94. Paolocci, N., et al. 2000. cGMP-independent inotropic effects of nitric oxide and peroxynitrite donors: potential role for nitrosylation. Am. J. Physiol. Heart Circ. Physiol. 279:H1982-H1988.
95. Hare, J.M. 2004. Nitroso-redox balance in the cardiovascular system. N. Engl. J. Med. 351:2112-2114.
96. Ferdinandy, P., Danial, H., Ambrus, I., Rothery, R.A., and Schulz, R. 2000. Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ. Res. 87:241-247.
97. Taylor, A.L., et al. 2004. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med. 351:2049-2057.
98. Maack, C., et al. 2003. Oxygen free radical release in human failing myocardium is associated wich increased activity of rac1-GTPase and represents a target for statin treatment. Circulation. 108:1567-1574.
99. Mak, S., and Newton, G.E. 2001. The oxidative stress hypothesis of congestive heart failure: radical thoughts. Chest. 120:2035-2046.
100. Jaatinen, P., Saukko, P., and Hervonen, A. 1993. Chronic ethanol exposure increases lipopigment accumulation in human heart. Alcohol Alcohol. 28:559-569.
101. Mak, S., and Newton, G.E. 2004. Redox modulation of the inotropic response to dobutamine is impaired in patients with heart failure. Am. J. Physiol. Heart Circ. Physiol. 286:H789-H795.
102. Cappola, T.P., et al. 2001. Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation. 104:2407-2411.
103. Doehner, W., et al. 2002. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation. 105:2619-2624.
104. Rossig, L., et al. 2001. Vitamin C inhibits endothelial cell apoptosis in congestive heart failure. Circulation. 104:2182-2187.
105. Packer, M., et al. 2001. Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344:1651-1658.
106. Hennekens, C.H., et al. 1996. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 334:1145-1149.
107. Yusuf, S., Dagenais, G., Pogue, J., Bosch, J., and Sleight, P. 2000. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 342:154-160.
108. Lonn, E., et al. 2002. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care. 25:1919-1927.
109. Freudenberger, R.S., et al. 2004. Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III - IV congestive heart failure. Expert Opin. Investig. Drugs. 13:1509-1516.
110. Giordano, F.J., and Johnson, R.S. 2001. Angiogenesis: the role of the microenvironment in flipping the switch. Curr. Opin. Genet. Dev. 11:35-40.
111. Ryan, H.E., Lo, J., and Johnson, R.S. 1998. HIF-1 alpha is required for solid tumor formation and embryonic vascularization. EMBO J. 17:3005-3015.
112. Carmeliet, P., et al. 1998. RoLe of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 394:485-490.
113. Iyer, N.V., et al. 1998. Cellular and developmental control of O2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 12:149-162.
114. Semenza, G.L. 2001. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell. 107:1-3.
115. Kaelin, W.G., Jr. 2002. Molecular basis of rhe VHL hereditary cancer syndrome. Nat. Rev. Cancer. 2:673-682.
116. Liu, Q., et al. 2004. A Fenton reaction at the endoplasmic reticulum is involved in the redox control of hypoxia-inducible gene expression. Proc. Natl. Acad. Sci. U. S. A. 101:4302-4307.
117. Cormier-Regard, S., Nguyen, S.V., and Claycomb, W.C. 1998. Adrenomedullin gene expression is developmentally regulated and induced by hypoxia in rat ventricular cardiac myocytes. J. Biol. Chem. 273:17787-17792.
118. Lee, P.J., et al. 1997. Hypoxia-inducible factor-1 mediates transcriptional activation of the heme oxygenase-1 gene in response to hypoxia. J. Biol. Chem. 272:5375-5381.
119. Semenza, G.L. 2004. O2-regulated gene expression: transcriptional control of cardiorespiratory physiology by HIF-1. J. Appl. Physiol. 96:1173-1177; discussion 1170-1172.
120. Lee, S.H., et al. 2000. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. N. Engl. J. Med. 342:626-633.
121. Park, S.K., et al. 2003. Hypoxia-induced gene expression occurs solely through the action of hypoxia-inducible factor 1alpha (HIF-1alpha): role of cytoplasmic trapping of HIF-2alpha. Mol. Cell. Biol. 23:4959-4971.
122. Lei, L., et al. 2004. Malignant transformation of heart muscle in the absence of the von Hippel-Lindau protein. Circulation. 110:III-45.
123. Batista, R.J., et al. 1997. Partial left ventriculectomy to treat end-stage heart disease. Ann. Thorac. Surg. 64:634-638.
124. Gorman, R.C., Jackson, B.M., and Gorman, J.H. 2004. The potential role of ventricular compressive therapy. Surg. Clin. North Am. 84:45-59.
125. Giordano, F.J., et al. 2001. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc. Natl. Acad. Sci. U. S. A. 98:5780-5785.